| Literature DB >> 34397698 |
Xiang-Bei Han1,2, Yan-Qiu Fang2, Shu-Xiang Liu1, Yan Tan2, Jun-Jie Hou2, Li-Jing Zhao1, Feng Li1.
Abstract
BACKGROUND: Advanced cancer (AC) patients experience serious physical and psychological problems with the disease progression. When approaching the end of life, these patients have to cope with not only the bodily illness, but also the spiritual crisis. Conventional psychological treatments reduce distress to a certain extent, but for patients with AC, especially when they face progressive illness and are approaching death, their psychological problems are complex, and no simple solutions are in sight. Therefore, we designed this study to evaluate the efficacy of the combined Naikan therapy (NT) and Morita therapy (MT) on psychological distress and posttraumatic growth in patients with AC.Entities:
Mesh:
Year: 2021 PMID: 34397698 PMCID: PMC8322545 DOI: 10.1097/MD.0000000000026701
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Patient demographic and clinical characteristics.
| Treatment | Control | |||
| Characteristic | No. (%) | No.% | χ2 | t |
| Sex | 0.14 | |||
| Male | 21 (32.30) | 23 (35.38) | ||
| Female | 44 (67.69) | 42 (64.62) | ||
| Age, yr | -0.05 | |||
| Mean | 58.04 | 58.19 | ||
| SD | 14.21 | 15.23 | ||
| Marital status | 0.14 | |||
| Currently married | 41 (63.07) | 43 (66.15) | ||
| Not currently married | 24 (36.92) | 22 (33.85) | ||
| Education | 0.03 | |||
| College degree or higher | 32 (49.23) | 31 (47.69) | ||
| Less than college degree | 33 (50.76) | 34 (52.31) | ||
| Primary cancer diagnosis | 0.5 | |||
| Breast | 25 (38.46) | 23 (35.38) | ||
| Lung | 11 (16.92) | 11 (16.92) | ||
| Colon or rectal | 19 (29.23) | 18 (27.69) | ||
| Renal | 10 (15.38) | 13 (20.00) | ||
| Stage | 0.15 | |||
| III | 45 (69.23) | 47 (72.31) | ||
| IV | 20 (30.77) | 18 (27.69) |
Figure 1CONSORT flow diagram.
Comparison of the score of the distress thermometer.
| The distress thermometer | The distress thermometer | ||||
| Pretreatment | treatment | control | Posttreatment | treatment | control |
| Median (IQR) | 4 (1) | 5 (2) | Median (IQR) | 2 (1) | 5 (2) |
| Mean (SD) | 4.62 (1.36) | 4.91 (1.38) | Mean (SD) | 2.42 (1.03) | 4.81 (1.43) |
| Wilcoxon test | |||||
| ANCOVA | |||||
Comparison of the score of the posttraumatic growth.
| OVERALL | Pretreatment | treatment | control | Posttreatment | treatment | control |
| median (IQR) | 43 (7) | 41 (8) | median (IQR) | 74 (8) | 45 (7) | |
| Wilcoxon test | W = 1432 | |||||
| ANCOVA | ||||||
| Relating to other | Pretreatment | treatment | control | Posttreatment | treatment | control |
| median (IQR) | 16 (6) | 16 (6) | median (IQR) | 27 (4) | 17 (6) | |
| Wilcoxon test | W = 1468 | |||||
| ANCOVA | ||||||
| New possibilities | Pretreatment | treatment | control | Posttreatment | treatment | control |
| median (IQR) | 11 (4) | 11 (4) | median (IQR) | 18 (3) | 11 (4) | |
| Wilcoxon test | W = 1783.5 | |||||
| ANCOVA | ||||||
| Personal strength | Pretreatment | treatment | control | Posttreatment | treatment | control |
| median (IQR) | 6 (4) | 6 (4) | median (IQR) | 14 (5) | 7 (4) | |
| Wilcoxon test | W = 1711 | |||||
| ANCOVA | ||||||
| Spiritual changes | Pretreatment | treatment | control | Posttreatment | treatment | control |
| median (IQR) | 4 (1) | 4 (3) | median (IQR) | 6 (2) | 4 (2) | |
| Wilcoxon test | W = 1985 | |||||
| ANCOVA | ||||||
| Appreciation of life | Pretreatment | treatment | control | Posttreatment | treatment | control |
| median (IQR) | 6 (4) | 5 (3) | median (IQR) | 10 (4) | 6 (2) | |
| Wilcoxon test | W = 1581.5 | |||||
| ANCOVA |
Comparison of the frequencies of the 10 most common problems endorsed.
| Pre-treatment | Post-treatment | ||||||
| Treatment (65) | Control (65) | Treatment (55) | Control (53) | ||||
| Variable | No. (%) | No. (%) | χ2 | No. (%) | No. (%) | χ2 | |
| Fears | 48 (73.85) | 46 (70.77) | 0.154 | 30 (54.55) | 40 (75.47) | 5.183 | .023 |
| Sleep/insomnia | 44 (67.69) | 45 (69.30) | 0.036 | 21 (38.18) | 39 (73.58) | 13.701 | .000 |
| Memory decline | 35 (53.85) | 33 (50.77) | 0.123 | 29 (52.73) | 28 (52.83) | 0.000 | .988 |
| Nervous, anxiety | 34 (52.31) | 35 (53.85) | 0.031 | 17 (30.91) | 27 (50.94) | 4.487 | .034 |
| Fatigue | 46 (70.77) | 41 (63.08) | 0.869 | 39 (70.91) | 42 (79.25) | 1.000 | .317 |
| Pain | 38 (58.46) | 37 (56.92) | 0.032 | 41 (74.55) | 36 (67.92) | 0.578 | .447 |
| Insurance/financial | 39 (60.00) | 41 (63.08) | 0.130 | 42 (76.36) | 38 (70.70) | 0.306 | .580 |
| Loss of appetite | 31 (47.69) | 33 (50.77) | 0.123 | 15 (27.27) | 30 (56.60) | 9.554 | .002 |
| Nausea/vomiting | 29 (44.62) | 26 (40.00) | 0.284 | 28 (50.91) | 25 (47.17) | 0.151 | .698 |
| Tingling hands/feet | 26 (40.00) | 25 (38.46) | 0.032 | 28 (50.91) | 24 (45.28) | 0.342 | .559 |